| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Specific target information for Yadanzioside C is not extensively reported in the available literature. As a quassinoid glucoside, it is expected to share similar mechanisms of action with other quassinoids, which may include inhibition of protein synthesis, induction of apoptosis, and modulation of inflammatory pathways. Further research is needed to identify and characterize its primary molecular targets.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for Yadanzioside C are not extensively reported in the available literature. As a quassinoid compound, it is expected to exhibit biological activities similar to other members of this class, including antitumor, anti-inflammatory, and antimicrobial properties. Further studies are needed to fully characterize its in vitro pharmacological profile.
|
| ln Vivo |
Specific in vivo activity data for Yadanzioside C are not extensively reported in the available literature. As a quassinoid glucoside, it may exhibit similar in vivo effects to other quassinoid compounds, including potential antitumor and anti-inflammatory activities. Further research is needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro assay for Yadanzioside C typically involves standard biochemical or cellular assays used for quassinoid compounds. These may include enzyme inhibition assays, cell viability assays, or receptor binding studies. The compound is tested at various concentrations, and the biological activity is quantified using appropriate readouts such as IC50 or EC50 values.
|
| Cell Assay |
The in vitro cellular assay for Yadanzioside C typically involves culturing cancer cell lines or other relevant cell types in appropriate growth media. Cells are treated with varying concentrations of the compound, and cell viability is assessed using standard assays such as MTT, SRB, or CellTiter-Glo. The antiproliferative effect is quantified by determining the half-maximal inhibitory concentration (IC50).
|
| Animal Protocol |
In vivo animal studies for Yadanzioside C would typically involve the use of mouse models of cancer or other diseases. Tumor-bearing mice would be administered the compound via appropriate routes (e.g., oral gavage or intraperitoneal injection) at various dose levels. Tumor growth inhibition would be monitored over several weeks, and endpoints would include tumor volume measurements, body weight changes, and histopathological analysis of tumor tissues.
|
| ADME/Pharmacokinetics |
Yadanzioside C has a molecular weight of 726.72 g/mol and a molecular formula of C34H46O17. The IUPAC name is methyl (1R,2S,3S,3aS,3a1R,4R,6aR,7aS,8S,11aS,11bR)-1,2-dihydroxy-4-(((E)-4-hydroxy-3,4-dimethylpent-2-enoyl)oxy)-8,11a-dimethyl-5,9-dioxo-10-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4,5,6a,7,7a,8,9,11a,11b-decahydro. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Yadanzioside C are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References | |
| Additional Infomation |
It has been reported that methyl (1R,2S,3R,6R,8S,9S,13S,14R,15R,16S)-15,16-dihydroxy-3-[(E)-4-hydroxy-3,4-dimethylpentanyl]oxy-9,13-dimethyl-4,10-dioxo-11-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxacyclohexane-2-yl]oxy-5,18-dioxapentane[12.5.0.01,6.02,17.08,13]nonadecan-11-en-17-carboxylic acid ester exists in the Brucea javanica, and relevant data are available.
Yadanzioside C is a quassinoid glucoside found in the seeds of Brucea amarissima. It is also known by its CAS number 95258-16-5 and has a purity of ≥98%. The compound is used in research to study the pharmacological properties of quassinoid natural products. It has not yet entered clinical trials and is strictly for preclinical research purposes. |
| Molecular Formula |
C34H46O17
|
|---|---|
| Molecular Weight |
726.71884
|
| Exact Mass |
726.274
|
| CAS # |
95258-16-5
|
| PubChem CID |
6436227
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
51
|
| Complexity |
1540
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]2C[C@@H]3[C@@]45COC([C@@H]4[C@H](C(=O)O3)OC(=O)/C=C(\C)/C(C)(C)O)([C@H]([C@@H]([C@@H]5[C@]2(C=C(C1=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)O)C(=O)OC
|
| InChi Key |
HOEZNQMKHRGGTI-WLSWEETJSA-N
|
| InChi Code |
InChI=1S/C34H46O17/c1-12(31(3,4)45)7-18(36)51-24-26-33-11-47-34(26,30(44)46-6)27(42)23(41)25(33)32(5)9-15(19(37)13(2)14(32)8-17(33)50-28(24)43)48-29-22(40)21(39)20(38)16(10-35)49-29/h7,9,13-14,16-17,20-27,29,35,38-42,45H,8,10-11H2,1-6H3/b12-7+/t13-,14-,16+,17+,20+,21-,22+,23+,24+,25+,26+,27-,29+,32-,33+,34?/m0/s1
|
| Chemical Name |
methyl (1R,2S,3R,6R,8S,9S,13S,14R,15R,16S)-15,16-dihydroxy-3-[(E)-4-hydroxy-3,4-dimethylpent-2-enoyl]oxy-9,13-dimethyl-4,10-dioxo-11-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-11-ene-17-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3760 mL | 6.8802 mL | 13.7605 mL | |
| 5 mM | 0.2752 mL | 1.3760 mL | 2.7521 mL | |
| 10 mM | 0.1376 mL | 0.6880 mL | 1.3760 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
